Top Picks for Trump’s Pro-Crypto America

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

Christina Ackermann net worth and biography

Christina Ackermann Biography and Net Worth

EVP of Bausch Health Companies

Christina Ackermann is Executive Vice President, General Counsel of the Company. Prior to joining Bausch Health, Ms. Ackermann was part of the Novartis group of companies for the 14 years, most recently serving as Senior Vice President, General Counsel for Alcon, where she was responsible for the Legal, Intellectual Property and Compliance functions. She previously served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers & acquisitions.

What is Christina Ackermann's net worth?: The estimated net worth of Christina Ackermann is at least $1.74 million as of June 2nd, 2021. Ms. Ackermann owns 227,103 shares of Bausch Health Companies stock worth more than $1,744,151 as of December 18th. This net worth estimate does not reflect any other assets that Ms. Ackermann may own. Learn More about Christina Ackermann's net worth.
How do I contact Christina Ackermann?: The corporate mailing address for Ms. Ackermann and other Bausch Health Companies executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Companies can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on Christina Ackermann's contact information.
Has Christina Ackermann been buying or selling shares of Bausch Health Companies?: Christina Ackermann has not been actively trading shares of Bausch Health Companies within the last three months. Most recently, Christina Ackermann sold 121,198 shares of the business's stock in a transaction on Wednesday, June 2nd. The shares were sold at an average price of $31.83, for a transaction totalling $3,857,732.34. Following the completion of the sale, the executive vice president now directly owns 227,103 shares of the company's stock, valued at $7,228,688.49. Learn More on Christina Ackermann's trading history.
Who are Bausch Health Companies' active insiders?: Bausch Health Companies' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Companies' active insiders.
Are insiders buying or selling shares of Bausch Health Companies?: In the last year, insiders at the sold shares 1 times. They sold a total of 13,370 shares worth more than $83,027.70. The most recent insider tranaction occured on September, 6th when EVP Seana Carson sold 13,370 shares worth more than $83,027.70. Insiders at Bausch Health Companies own 8.1% of the company. Learn More about insider trades at Bausch Health Companies.
Information on this page was last updated on 9/6/2024.

Christina Ackermann Insider Trading History at Bausch Health Companies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2021	Sell	121,198	$31.83	$3,857,732.34	227,103
3/10/2020	Buy	4,390	$18.25	$80,117.50	87,245
8/12/2019	Sell	3,418	$22.45	$76,734.10
7/11/2019	Sell	3,968	$24.81	$98,446.08
10/16/2018	Sell	19,946	$24.98	$498,251.08

Christina Ackermann Buying and Selling Activity at Bausch Health Companies

Bausch Health Companies Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $7.66

$7.63

$7.79

50 Day Range

MA: $8.37

$7.59

$9.78

2 Week Range

Now: $7.66

$3.96

$11.46

Volume

782,907 shs

Average Volume

2,759,493 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69